StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Jay Thakkar, ICICI Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byJay Thakkar, ICICI SecuritiesHorizon: NA (inferred Intraday)22 Sept 2026, 3:19 pm ISTvia Zee Business (Live)

Entry₹2,472Inferred
Target₹2,515
Total upside +1.74% (call closed)
Stop loss₹2,430-1.70% risk
At expiry₹2,471.723 Sept 2026, 3:05 pm
Expired-0.01%
Follow Jay Thakkar for new callsGet alertsWatch GLENMARK for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 23 Sept 2026
4 supporting0 opposing
Supports the BUY call (4)

Glenmark Pharmaceuticals' Goa facility received an Establishment Inspection Report (EIS) from the U.S. FDA with a Voluntary Action Indicated (VAI) classification, suggesting no major compliance issues

BSE · Company Update·23 Sept · today

(opens in new tab)

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·23 Sept · today

Glenmark Pharmaceuticals Ltd spurts 0.5%, gains for fifth straight session

NewsGoogle News·22 Sept · yesterday

(opens in new tab)

Pharma Stocks Rally: BSE Healthcare index hits new high, Sun Pharma, Torrent Pharma, Glenmark gain up to 5%

NewsGoogle News·21 Sept · 2d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Jay Thakkar, ICICI Securities

Every call and its outcome